Hepatitis C

Cost-effectiveness of Total State Coverage for Hepatitis C Medications

May 20th 2021, 1:00pm


Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.

Discovery of Hepatitis C Virus Brings Nobel Prize

October 5th 2020, 11:12am


Two Americans and a British scientist share the 2020 Prize for Physiology or Medicine for work in the 1970s through the 1990s. The rise of agents to treat hepatitis C virus has created vexing questions in managed care.

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

April 17th 2020, 7:55pm


Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

March 2nd 2020, 9:00pm


Hepatitis C virus (HCV) has contributed to more US patient deaths than the next 60 reportable infectious diseases combined. The United States Preventive Services Task Force has issued updated guidelines on screening for HCV that account for the larger proportion of this patient group that now includes persons who inject drugs, as well as the shift from interferon-based therapy to regimens composed of direct-acting antiviral (DAA) medications.

From the Editorial Board: Jeffrey D. Dunn, PharmD, MBA

February 15th 2020, 12:00am


Discontinuation of New Hepatitis C Drugs Among Medicare Patients

February 12th 2020, 7:00pm


Real-world discontinuation of hepatitis C drugs was low, but it was 3 times more likely than in clinical trials and varied by patient characteristics.

Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients

December 13th 2019, 9:43pm


Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.

Podcast: This Week in Managed Care—Opioid Ruling and Settlement, and Other Health News

September 1st 2019, 4:00pm


Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

What We're Reading: State-Based ACA Exchange; Surgeon General on Marijuana Use; HCV Drugs and Liver Impairment

August 30th 2019, 5:09pm


Maine wants to take more control over its Affordable Care Act marketplace; Surgeon General Jerome Adams, MD, MPH, has issued an advisory against marijuana use in young people and pregnant people; the FDA is warning of rare occurrences of serious liver injury from use of 3 hepatitis C virus (HCV) drugs.

This Week in Managed Care: August 30, 2019

August 30th 2019, 5:00pm


This week, the top managed care stories included a huge ruling against one opioid maker and a settlement offer from another; an expert panel calling for broader screening for hepatitis C; a review showing there are more fatal events linked to a multiple sclerosis drug than previously known.